Theravance Bio stock falls more than 20% after drug trial disappoints

Shares of Theravance Biopharma Inc. TBPH, +0.85% fell much than 20% successful the extended league Monday aft the biopharmaceutical institution said that a dose-finding survey of 1 of its drugs, izencitinib, didn't measurement up to a placebo successful the attraction of ulcerative colitis. The institution said it volition look astatine the information to amended recognize findings and imaginable for the drug. The banal ended the regular trading time up 0.9%.